Beeldvorming met radioactief TRM-1 bij patienten met solide kanker in gevorderd stadium, die worden behandeld met gemcitabine, cisplatin en TRM-1.

1. Histologically or cytologically confirmed advanced solid malignancy in a subject who has relapsed after or is refractory to standard therapy, for whom no standard therapy exists, or for whom the combination of gemcitabine and cisplatin is considered an appropriate standard treatment;

2. Measurable (according to the RECIST Criteria) or evaluable disease;

3. Adequate hematologic function and bone marrow reserve:

A. Absolute neutrophil count (ANC) ¡Ý 1.5 x 109/L;

B. Platelet (PLT) count ¡Ý 100 x 109/L;

C. Hemoglobin ¡Ý 5.6 mmol/L.

4. Adequate hepatic and renal function:

A. ASAT and ALAT ¡Ü 2.5 fold upper limit of normal (ULN);

B. Bilirubin ¡Ü 1.25 fold ULN;

C. Creatinine ¡Ü 1.25 fold ULN or calculated creatinine clearance ¡Ý 60 mL/min.

5. Performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) Scale;

6. Life expectancy of at least 3 months;

7. Age of 18 or older;

8. Have the ability to understand the requirements of the study, provide written informed consent (including consent for the use and disclosure of research-related health information), and comply with the study protocol procedures.

1. Any co-morbid condition that in the judgment of the investigator renders the subject at high risk of treatment complication or reduces the probability of assessing clinical effect;

2. Cytotoxic agent, hormonal therapy, or radiation therapy within 3 weeks (6 weeks for nitrosoureas or mitomycin-C) prior to day 1, cycle 1; investigational agent within 4 weeks prior to day 1, cycle 1;

3. Monoclonal antibody (including investigational monoclonal antibodies) within 3 weeks (murine or chimeric) or 8 weeks (human or humanized) prior to day 1, cycle 1;

4. Systemic steroids within 1 week prior to day 1, cycle 1 except steroids used as part of an antiemetic regimen or maintenance-dose steroids for non-cancerous disease;

5. Major surgery within 4 weeks prior to day 1, cycle 1;

6. Persistent grade 2 or greater toxicity (NCI-CTCAE, version 3.0, 12 December 2003) related to prior therapy (except alopecia);

7. Any grade 2 or greater neuropathy;

8. Hearing loss requiring the use of a hearing aid;

9. History of any infection requiring hospitalization or antibiotics within 2 weeks prior to day 1, cycle 1;

10. Myocardial infarction (MI), cerebrovascular accident (CVA), or ¡Ý Class III congestive heart failure (CHF) according to the New York Heart Association Classification for within 6 months prior to day 1, cycle 1;

11. Known brain metastases unless adequately treated (surgery or radiotherapy), with no evidence of progression and neurologically stable off anticonvulsants and steroids;

12. Known human immunodeficiency virus (HIV) infection;

13. Known chronic or acute viral hepatitis;

14. Pregnant or breast-feeding women. Women with an intact uterus (unless amenorrheic for the last 24 months) must have a negative serum pregnancy test at screening. All non-sterile, non-postmenopausal females must agree to use a medically approved method of contraception during the study and for 60 days following the final dose;

15. Males who do not agree to use effective contraception during the study and for a period of 60 days following the final dose.